Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Opicinumab - Biogen

Drug Profile

Opicinumab - Biogen

Alternative Names: Anti-LINGO 1; Anti-LINGO-1 antibody; BIIB-033

Latest Information Update: 15 Jan 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biogen Idec; Dyax
  • Developer Biogen
  • Class Antibodies; Eye disorder therapies; Monoclonal antibodies; Neuroprotectants; Neuropsychotherapeutics
  • Mechanism of Action Cell differentiation stimulants; LINGO 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Multiple sclerosis; Optic neuritis

Most Recent Events

  • 08 Jan 2019 Shire has been acquired and merged into Takeda
  • 30 Sep 2018 Biogen completes enrolment in the phase IIb AFFINITY trial for Multiple sclerosis (Adjunctive treatment) in Australia, Belgium, Canada, Czech Republic, France, Germany, Switzerland, Netherlands, Poland, Spain, Hungary, Italy, United Kingdom (IV) (NCT03222973)
  • 25 Oct 2017 Pharmacodynamics data from a preclinical trial in Optic neuritis presented at the 7th Joint ECTRIMS – ACTRIMS meeting (ECTRIMS – ACTRIMS - 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top